Description: Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
Home Page: www.kalarx.com
KALA Technical Analysis
1167 Massachusetts Avenue
Arlington,
MA
02476
United States
Phone:
781 996 5252
Officers
| Name | Title |
|---|---|
| Mr. Mark T. Iwicki | Chairman & CEO |
| Mr. Todd Bazemore | Pres & COO |
| Dr. Kim Brazzell Ph.D. | Head of R&D and Chief Medical Officer |
| Dr. Justin Hanes Ph.D. | Founder & Chair of the Scientific Advisory Board |
| Ms. Mary Reumuth CPA, CPA | CFO & Treasurer |
| Ms. Jill S. Steier | Exec. Director of Investor Relations & Corp. Communications |
| Mr. Eric L. Trachtenberg | Gen. Counsel, Chief Compliance Officer & Corp. Sec. |
| Ms. Michele LaRussa | Sr. VP of Regulatory Affairs & Quality Assurance |
| Mr. Vincent Kosewski | Sr. VP of Manufacturing & Supply Chain Management |
| Mr. James Patnoe | Sr. VP of Market Access, Commercial Operations & Pricing |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9441 |
| Price-to-Sales TTM: | 1.157 |
| IPO Date: | 2017-07-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 192 |